Eric WERSINGER (EN)

UMR 1107 INSERM/UCA Neuro-Dol
Facultés de Médecine et Pharmacie
Place Henri Dunant
63001 Clermont-Ferrand
FRANCE

Dr. Eric WERSINGER

Assistant Professor
Fundamental Pharmacology and Pain Clinic Team, Team FPPC – Pain and Cancer Axis

eric.wersinger@-Code to remove to avoid SPAM-uca.fr

Research Theme:

In this Pain and Cancer axis, my research activity focuses on the physiopathological mechanisms of peripheral neuropathies induced by chemotherapy treatments (CINP) causing disabling symptoms in patients and for which the need for medical innovation is important and not satisfied. The study of changes in expression and function of ion channels such as HCN channels but also of receptors for mediators expressed in peripheral neurons (DRG-TG) is necessary to better understand variations in neuronal activities and ultimately the rapid onset of symptoms and their chronicization. The implementation of new cellular models (IPSCs, organoids); The use of validated preclinical models of NCI and various techniques, notably imaging and electrophysiology, allow us to more precisely study these molecular targets of interest and determine their pharmacological potential to reduce NCI in patients.

Teachings:

Biophysics, pharmaceutical biomathematics department: Pharmacy (DFGSP, DFASP, Internat);
PASS/PASS-R;
Bachelor’s degree in Life science – Pharmacology and Nutrition;
Orthoptics 1st and 2nd year;
Speech therapy 3rd year;
Thesis and M2 co-supervision.

Responsibilities:

Member of the UFR Pharmacy Council;
Certificate of Pharmaceutical Synthesis (CSP) working group.

Website:

https://orcid.org/0009-0004-8195-3395

HAL Publications

Journal articles

2019

ref_biblio: Sercan Deniz, Eric Wersinger, Serge Picaud, Michel J Roux. Evidence for functional GABAA but not GABAC receptors on mouse cone photoreceptors. Visual Neuroscience, 2019, 36, pp.E005. ⟨10.1017/S0952523819000038⟩. ⟨hal-02342212⟩
Accès au texte intégral et bibtex

2018

ref_biblio: Frederic Venail, Pierre Attali, Eric Wersinger, Roberto Gomeni, Sonia Maria Poli, et al.. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H 4 receptor inhibitor SENS-111 using a modified caloric test in healthy subjects. British Journal of Clinical Pharmacology, 2018, 84 (12), pp.2836-2848. ⟨10.1111/bcp.13744⟩. ⟨hal-02315424⟩
Accès au bibtex

2016

ref_biblio: P. Attali, R. Gomeni, E. Wersinger, S. Poli, F. Venail. The Effects of SENS-111, A New H4R Antagonist, On Vertigo Induced by Caloric Test in Healthy Volunteers (HV) is Related to Plasma Concentrations. Clinical Therapeutics, 2016, 38 (10S), pp.e4. ⟨10.1016/j.clinthera.2016.07.024⟩. ⟨hal-01818970⟩
Accès au bibtex

2011

ref_biblio: Sercan Deniz, Eric Wersinger, Yannick Schwab, Carole Mura, Ferenc Erdelyi, et al.. Mammalian retinal horizontal cells are unconventional GABAergic neurons. Journal of Neurochemistry, 2011, 116 (3), pp.350-362. ⟨10.1111/j.1471-4159.2010.07114.x⟩. ⟨hal-04286685⟩
Accès au bibtex

2006

ref_biblio: Eric Wersinger, Yannick Schwab, José-Alain Sahel, Alvaro Rendon, David Pow, et al.. The glutamate transporter EAAT5 works as a presynaptic receptor in mouse rod bipolar cells. The Journal of Physiology, 2006, 577 (1), pp.221-234. ⟨10.1113/jphysiol.2006.118281⟩. ⟨hal-04098634⟩
Accès au bibtex

Poster communications

2022

ref_biblio: M. Morez, L. Prival, Y. Aissouni, E. Bourinet, O. Roy, et al.. Disrupting HCN channels – TRIP8b interaction is an efficient strategy to decrease acute oxaliplatin-induced peripheral neuropathy symptoms.. IASP 2022 World Congress on pain, Sep 2022, Toronto, Canada. ⟨hal-04068893⟩
Accès au bibtex

Proceedings

2022

ref_biblio: M. Morez, Y. Aissouni, L. Prival, J. Barbier, D. Balayssac, et al.. Modulation of HCN channel activity in oxaliplatin-induced peripheral neuropathy.. Fundamental & Clinical Pharmacology, 36 (S1), pp.10-11, 2022, ⟨10.1111/fcp.12786⟩. ⟨hal-04026980⟩
Accès au bibtex